FDA OKs Leuprolide Mesylate 3-Month Formulation in Advanced Prostate Cancer
Results from a phase 3 trial led to the approval of leuprolide mesylate as a 3-month formulation for patients with advanced prostate cancer.
Previous Post
Presymptomatic treatment of spinal muscular atrophy with risdiplam leads to improved functional outcomes
Next Post
Riz Ahmed Hospitalized for “Something Silent and Intense” Filming Rogue One
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago